(redirected from Aromatase inhibitors)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to Aromatase inhibitors: tamoxifen
See: deterrent
References in periodicals archive ?
The Breakthrough Therapy designation for entinostat is based on data from the completed Phase 2 ENCORE 301 study, in which entinostat was shown to extend both progression-free survival and overall survival when added to exemestane in postmenopausal women with ER+ metastatic breast cancer whose cancer had progressed after treatment with a nonsteroidal aromatase inhibitor and with a very acceptable tolerability profile.
One option is to take tamoxifen for five years followed by aromatase inhibitors for another five years giving you 10 years of protection.
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
Data Source: Prospective cohort study of 156 postmenopausal nonosteoporotic women using adjuvant aromatase inhibitors in early breast cancer.
Adjuvant aromatase inhibitor (AI) therapy, administered either alone for 5 years or sequentially with adjuvant tamoxifen, improves disease-free survival in postmenopausal women with endocrine-responsive breast cancer when compared with tamoxifen alone [2-5].
FEELING BETTER: Stephanie Boyle, of North Tyneside, has been treated with aromatase inhibitors
If there are no appeals against the FAD, the final guidance on the use of aromatase inhibitors in early breast cancer is due to be published by NICE in November this year; formalising the recommendations.
Aromatase inhibitors stop the natural production of oestrogen - the hormone that is responsible for the growth and recurrence of many breast cancers.
Femara is a type of drug called an aromatase inhibitor which stops the natural production of oestrogen - the hormone that is responsible for the growth and recurrence of many breast cancers.
Unlike tamoxifen, which works by blocking estrogen receptors on cells, the aromatase inhibitors anastrazole (Arimidex), exemestane (Aromasin) and letrozole (Femara) work by preventing androgen hormones from turning into estrogen in the first place.
Evidence for new non-steroidal human aromatase inhibitors and comparison with equine aromatase inhibition for an understanding of the mammalian active site.
Called the ExCel research study, this is the first North American clinical trial to evaluate how a class of drugs called aromatase inhibitors prevents the disease.